European regulators reaffirm Apellis’ rejection, add eight positive recommendations
Apellis has had its European ambitions dashed once again after regulators reaffirmed their decision to not recommend the company’s treatment for geographic atrophy due to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.